---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059338"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:59:07.005157+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma shareholders elect three Class I directors, ratify EY, approve say-on-pay

## Summary
- Elected Eran Broshy, James Kelly, Laurie Smaldone Alsup as Class I directors for three-year terms; votes for each exceeded 35 million.
- Ratified Ernst & Young as independent auditor for FY 2024 with 39,257,982 for, 228,078 against.
- Non-binding advisory resolution on named executive officer compensation passed with 35,205,714 for, 332,345 against.
- Total shares voted at annual meeting: 39,493,689 (81.3% of outstanding).

## SEC filing metadata
- accession: 0001104659-24-059338
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/tm2413991d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059338
- JSON: https://secwatch.observer/filing/0001104659-24-059338.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059338.txt

## Key facts
- Shareholder Votes
  Theravance Biopharma, Inc. shareholders approved Election of Class I directors: Eran Broshy, James Kelly, Laurie Smaldone Alsup at the 2024-05-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-05-08
  source text: Proposal One – Based on the following results of voting, the nominees listed below were elected Class I directors to serve as members of the Board until the Company’s Annual General Meeting held in 2026 and until their successors are duly elected and qualified: Nominees For Against Abstain Broker Non- Votes Eran Broshy 35,316,310 223,797 635 3,952,947 James Kelly 35,265,676 274,631 435 3,952,947 Laurie Smaldone Alsup 35,290,841 240,365 9,536 3,952,947
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm
- Shareholder Votes
  Theravance Biopharma, Inc. shareholders approved Non-binding advisory resolution regarding compensation of named executive officers at the 2024-05-08 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2024-05-08
  source text: Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non- Votes Number of Shares Voted 35,205,714 332,345 2,683 3,952,947
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm
- Shareholder Votes
  Theravance Biopharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-08 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-05-08
  source text: Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified: For Against Abstain Broker Non- Votes Number of Shares Voted 39,257,982 228,078 7,629 N/A
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.